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The  1p/ 19q genotype predicts chemosensitivity in oligodendroglial neoplasms, but some with intact 1p/19q also respond and
not all with 1p/19q loss derive durable benefit from chemotherapy. We have evaluated the predictive and prognostic significance
of pretherapy
201Tl and
18F-FDG SPECT and genotype in 38 primary and 10 recurrent oligodendroglial neoplasms following
PCV chemotherapy. 1p/19q loss was seen in 8/15 OII, 6/15 OAII, 7/7 OIII, 3/11 OAIII and was associated with response (Fisher-
Exact: P¼0.000) and prolonged progression-free (log-rank: P¼0.002) and overall survival (OS) (log-rank: P¼0.0048). Response
was unrelated to metabolism, with tumours with high or low metabolism showing response. Increased
18F-FDG or
201Tl uptake
predicted shorter progression-free survival (PFS) in the series (log-rank:
201Tl P¼0.0097,
18F-FDG P¼0.0170) and in cases with or
without the  1p/ 19q genotype. Elevated metabolism was associated with shorter OS in cases with intact 1p/19q (log-rank:
18F-
FDG P¼0.0077;
201Tl P¼0.0004) and shorter PFS in responders (log-rank:
18F-FDG P¼0.005;
201Tl P¼0.0132).
201Tl uptake and
1p/19q loss were independent predictors of survival in multivariate analysis. In this initial study,
201Tl and
18F-FDG uptake did not
predict response to PCV, but may be associated with poor survival following therapy irrespective of genotype. This may be clinically
useful warranting further study.
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Oligodendroglial neoplasms with the  1p/ 19q genotype have a
more indolent clinical evolution, are associated with prolonged
survival and are more likely to be chemosensitive than their
morphologically equivalent counterparts with intact 1p/19q
(Cairncross et al, 1998; Smith et al, 2000; van den Bent, 2004).
The biological basis behind these clinical differences are not yet
well understood, but are likely to result from complex inter-
actions between tumour genetics and host environment, as well as
physiological factors that determine drug delivery (Warnke et al,
2003, 2005; Hartmann et al, 2004; Jeuken et al, 2004). Genotype
and factors such as blood flow or blood volume and metabolism
have been associated with chemoresponsiveness in anaplastic
oligodendrogliomas (Warnke, 1998; Engelhard et al, 2003; Jager
et al, 2005). Despite responsiveness to therapy, oligodendroglial
neoplasms with the  1p/ 19q genotype inevitably recur, some-
times with only short progression-free survival (PFS). Prognostic
or predictive factors that may be used to identify patients likely to
derive durable clinical benefit are therefore essential.
Metabolic imaging using radiolabeled tracers such as
201Thallium or
18F-fluorodeoxyglucose has been used in a number
of glioma studies, to yield diagnostic or prognostic information
(Benard et al, 2003; Padma et al, 2003; Datta et al, 2004), to
guide biopsy (Levivier et al, 2002), to distinguish recurrent tumour
from radiation necrosis (Stokkel et al, 1999) or monitor response
to therapy (Vos et al, 2003) but the relationship between
metabolism and chemosensitivity in oligodendroglial neoplasms
has still to be determined.
In a multidisciplinary study of oligodendroglial neoplasms
undergoing therapy at a single UK treatment centre between 2000
and 2003, the  1p/ 19q genotype was associated with a more
indolent clinical history with longer time to first oncology therapy
and prolonged survival from first referral, than cases with intact
1p/19q (Walker et al, 2005). Response and favourable outcome
following procarbazine, lomustine and vincristine (PCV) chemo-
therapy was strongly associated with the  1p/ 19q genotype
(Walker et al, 2006). No relationship was observed between
pretherapy single-voxel Magnetic Resonance Spectroscopy and
genotype (Jenkinson et al, 2005). In contrast, pretherapy brain
Single-Photon Emission Computed Tomography (SPECT) data
revealed that tumours with 1p/19q loss were more likely to show
increased
201thallium uptake and to a lesser degree,
18F-fluorodeoxy-
glucose uptake than those without these losses (Walker et al, 2004).
The aim of the present study was to determine whether
pre-therapy
201Tl or
18F-FDG SPECT may be used to predict
therapeutic response and outcome in oligodendroglial neo-
plasms treated with PCV chemotherapy and to compare this
with genotype.
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Case selection and pathology
Cases for investigation were from a prospective study of adult
oligodendroglial tumours at the Walton Centre for Neurology and
Neurosurgery/Clatterbridge Center for Oncology diagnosed between
May 2000 and July 2003 (Walker et al, 2005). For inclusion in this
study, patients had pathology diagnosis and SPECT data pretherapy,
were treated by PCV chemotherapy and gave research consent. Cases
in this study were included in larger series reporting pretherapy
associations between SPECT data, genotype and histopathology
(n¼59) (Walker et al, 2004) and between genotype and response
to PCV chemotherapy (n¼76) (Walker et al, 2006). The study had
local ethics committee approval. Consensus pathological diagnosis
and grading according to current WHO criteria (Kleihues and
Cavanee, 2000) was undertaken by two consultant neuropathologists.
The study included 38 previously untreated patients (11 oligoden-
droglioma WHO grade II (OII), 14 oligoastrocytoma WHO grade II
(OAII), five oligodendroglioma WHO grade III (OIII), eight
oligoastrocytoma WHO grade III (OAIII)) and 10 with tumours
that recurred following previous radiotherapy (four OII, one OAII,
two OIII, three OAIII). The median time between previous radio-
therapy and metabolic imaging was 5.7 years (range 1.1–13.9 years).
The median age was 43 (range 27–71). All patients had surgery prior
to therapy. In all, 94% had biopsy only (three image-guided, 42
serial-stereotactic). Three patients had a partial resection with
residual tumour clearly assessable on MRI postsurgery and before
nuclear medicine imaging.
201Tl SPECT and
18F-FDG imaging
Nuclear medicine imaging was post surgery and pretherapy for 47
patients. One patient had imaging before biopsy and therapy. The
median time from surgery to imaging was 19 days (range  21–301
days); 98% had imaging within 2 months of surgery. All cases had
tumour clearly visible on MR or CT at the time of imaging with
cross sectional area 410cm
2 (median 30cm
2 (range 10–74cm
2)).
201Thallium (
201Tl) SPECT and
18F-2-Fluoro-2-deoxy-D-glucose
(
18F-FDG) SPECT scans were obtained using a dual headed
collimated gamma camera (DSTXL GESMVI, 1998). Images were
acquired, reconstructed and reported using standard protocols as
described previously (Walker et al, 2004). The spatial resolution of
SPECT was 5mm.
18F-FDG uptake was assessed as hypermetabolic
or hypometabolic, if the intensity of signal within the known site
of tumour was greater than or less than the equivalent site in
the contralateral hemisphere, respectively. Similarly, scans were
reported as having either increased or normal
201Tl uptake at the
site of the tumour compared with the contralateral hemisphere.
Semiquantitative data was obtained as described previously
(Walker et al, 2004). Reconstructed transverse slices in interfile
format were imported into NIH Image (http://rsb.info.nih.gov/
nih-image). The tumour was located by comparison with MR or
CT images and regions of interest (ROI) that delineated the part of
tumour with the greatest difference in signal intensity and
representative of the most aggressive biology were drawn. Uptake
of
201Tl or
18F-FDG was measured in an axial slice containing the
selected ROI and expressed as the ratio of the mean tumour counts
in the ROI and the mean activity in an equivalent ROI mirrored
in the contralateral hemisphere.
18F-FDG and
201Tl SPECT data
reported as hypermetabolic or increased had uptake relative to the
contralateral brain of 40.9 and 41.1, respectively. Postsurgery
and pretherapy
201Tl SPECT data was available for 46 patients and
18F-FDG SPECT for 48 patients.
Chemotherapy
Chemotherapy followed nuclear medicine imaging, with median
time interval 19 days (range 2–152 days); 92% had therapy
within 2 months of imaging. PCV chemotherapy was administered
according to standard clinical protocols (Levin et al, 1980).
Lomustine (CCNU) (110mgm
 2), procarbazine (60mgm
 2) and
vincristine (1.4mgm
 2 (maximum 2mg)) were given on Days 1,
8–21 and 8 and 29, respectively. Cycles were repeated every 6
weeks for a maximum of six cycles. The median pretherapy
performance status, assessed using the ECOG scale, was 1 (range
0–4). Two high-grade cases died before completing the first cycle,
the remainder received a median of four cycles with 33%
completing six cycles. PCV was discontinued after cycle 1 in
three cases, and treatment continued with temozolomide (2) or
radiotherapy (1).
Response assessment
Response was assessed as described previously (Walker et al,
2006). A consultant neuroradiologist reviewed all available MR or
CT images taken before, during and after chemotherapy, and
at follow-up without knowledge of SPECT data, genotype or other
clinical factors. The largest perpendicular diameters of the tumour
were measured in axial sections of contrast-enhanced regions
of T1-weighted MR or CT images or T2-weighted MR images. In 31
enhancing cases, response was assessed using Macdonald criteria
(Macdonald et al, 1990). Response categories were: – CR-complete
response (disappearance of all tumour, off steroids and neuro-
logically stable or improved); PR – partial response (50% or
greater reduction in cross-sectional area, steroids stable or
reduced, and neurologically stable or improved); PD – progressive
disease (25% or greater increase in cross sectional area or any new
tumour on CT/MR images and/or neurologically worse with
steroids stable or increased); SD – stable disease (all other
situations). In 10 nonenhancing cases and three for whom contrast
enhancement was not assessable, response was assessed using
T2-weighted images (Hoang-Xuan et al, 2004; Stege et al, 2005). An
additional minor response (MR) category (425–o50% reduction
in cross-sectional area, steroids stable or reduced, and neuro-
logically stable or improved) was included, as some cases
showed radiological reduction in cross sectional T2W area of
425–o50%, accompanied by clinical benefit. None of the
enhancing cases had radiological changes in this range. Response
was not assessed due to early death (two cases) or insufficient
imaging data (two cases).
Clinical information
Information regarding current management, follow-up and out-
come was collected prospectively. Progression-free survival and OS
were calculated from the start of PCV. The median follow-up time
was 25 months (range 1–57) from start of chemotherapy and 40
months (range 16–57) for the 28 patients alive at study.
Molecular genetics
For each case regions of tumour histology in pretherapy resected
tumours or biopsy specimens representative of the most aggressive
tissue available and the overall pathology diagnosis were selected
for study. Laser capture microdissection was used to enrich the
tumour component in the samples for analysis and determination
of allelic imbalance was carried out using paired normal and
tumour samples and multiple simultaneous PCR amplification of a
panel of microsatellite markers, followed by capillary electrophor-
esis and data analysis as described previously (Walker et al, 2003,
2004). The microsatellite panel included: chromosome 1- D1S2667,
D1S508, D1S214 (1p36); chromosome 19- D19S412, D19S112,
D19S596 (19q13). Additional markers, D1S468, D1S2795 (1p36)
and D19S217, D19S572 (19q13) were used for cases that lacked
informativity for given loci.
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Statistical analysis was performed using SPSS. The Mann–Whitney
test was used for non-normally distributed SPECT data and w
2 or
Fisher’s Exact tests were used for categorical data. Kaplan–Meier
survival curves were obtained and differences in PFS or OS were
tested for statistical significance using the log-rank test. Univariate
and multivariate analysis was used to determine if genotype,
201Tl
and
18F-FDG uptake, gender, age, ECOG status, histopathology
grade and subtype, contrast enhancement, therapy for primary
or recurrent tumour had prognostic significance with respect
to survival. Cox Regression multivariate analysis for factors
significantly associated with survival in univariate analysis was
by forward stepwise entry of parameters at a significance of
0.05 for entry and 0.01 for removal. P-values (two-tailed) o0.05–
0.01 were considered weakly significant and those o0.01 of greater
significance.
RESULTS
SPECT data, histopathology and genotype
Associations of SPECT data with histopathology and genotype
have been reported previously in a larger series (Walker et al,
2004). In this subgroup of the original series, loss of 1p36 and
19q13 was found in 8/15 OII, 6/15 OAII, 7/7 OIII, 3/11 OAIII and
associations of SPECT data with genotype and histopathology
grade are given in Table 1. Increased
201Tl uptake was seen in 6/15
OII, 1/13 OAII, 5/7 OIII and 9/11 OAIII.
18F-FDG hypermetabolism
was present in 4/15 OII, 2/15 OAII, 3/7 OIII, 6/11 OAIII. Using
categorical or semiquantitative analyses, tumours with grade III
pathology were more likely to show
18F-FDG hypermetabolism or
increased
201Tl uptake than grade II cases. Similarly, increased
uptake of
201Tl was more likely in cases with loss of 1p36 and
19q13 than in cases without these losses in the series, in grade II
cases (Fisher-Exact- 1p/19q loss 6/13, 1p/19q intact 1/15 P¼0.029,
Mann–Whitney P¼0.001) and primary tumours (w
2 – 1p/19q loss
10/18, 1p/19q intact 3/18 P¼0.015, Mann–Whitney P¼0.015).
There was no association between the  1p/ 19q genotype and
18F-FDG uptake. Five grade II cases with loss of 1p36 and 19q13
were hypermetabolic and had increased uptake of thallium, but
no grade II cases with intact 1p36 and 19q13 had both features
of elevated metabolism (Fisher Exact: P¼0.013). There was no
difference in
18F-FDG uptake in primary vs recurrent tumours
(Table 1). Increased
201Tl uptake was more likely in the recurrent
cases, however 50% of recurrent cases had grade III pathology
compared with 34% of primary cases.
Response
Response, assessed in 44 cases given 41 cycle of chemotherapy
(41 PCV, two PCVþtemozolomide, one PCVþxrt), was signifi-
Table 1 Pretherapy SPECT data
18F-FDG uptake
201Tl uptake
n Number hypermetabolic P* Median (range) PB n Number increased P* Median (range) PB
Grade II 30 6 0.030 0.8 (0.5–2.4) 0.050 28 7 0.000 1.0 (0.8–7.6) 0.002
Grade III 18 9 1.1 (0.7–2.4) 18 14 3.3 (0.9–8.7)
Cases with loss of 1p36/19q13 24 10 0.12 0.9 (0.5–2.4) 0.24 23 14 0.038 2.1 (0.9–7.6) 0.047
Cases without loss of 1p36/19q13 24 5 0.8 (0.5–2.0) 23 7 1.0 (0.8–8.7)
Primary tumours 38 10 0.15 0.8 (0.5–2.4) 0.431 36 13 0.014 1.0 (0.8–8.7) 0.013
Recurrent tumours 10 5 1.1(0.5–2.4) 10 8 3.0 (1.0–8.2)
Pretherapy SPECT data in groups according to histology grade, genotype or therapy given to primary or recurrent tumour. Data given as n – number of cases in each group, the
number showing
18F-FDG hypermetabolism or increased
201Tl uptake and the median and range for each group. P – probability calculated using * w
2 test; B Mann–Whitney
test. Weakly significant P values are given in italics; those of greater significance are given in bold.
Table 2 Response to chemotherapy
RESPONSE
Loss of 1p36 and 19q13
18F-FDG uptake
201Tl uptake
Yes No P Hypometabolic Hypermetabolic P normal increased P
All cases 20/22 (91%) 7/22 (32%) 0.000 17/30 (57%) 10/14 (71%) 0.509 15/24 (63%) 12/18 (67%) 1.0
Primary tumours 15/17 (88%) 7/17 (41%) 0.010 15/25 (60%) 7/9 (78%) 0.439 14/22 (64%) 8/10 (80%) 0.440
Recurrent tumours 5/5 (100%) 0/5 (0%) 0.008 2/5 (40%) 3/5 (60%) 1.0 1/2 (50%) 4/8 (50%) 1.0
Grade II 13/14 (93%) 6/16 (38%) 0.002 13/24 (54%) 6/6 (100%) 0.061 13/21 (62%) 6/7 (86%) 0.371
Grade III 7/8 (88%) 1/6 (17%) 0.026 4/6 (67%) 4/8 (50%) 0.627 2/3 (67%) 6/11 (55%) 1.0
1p36/ 19q13 loss 11/12 (92%) 9/10 (90%) 1.0 8/8 (100%) 12/13 (92%) 1.0
1p36/19q13 intact 6/18 (33%) 1/4 (25%) 1.0 7/16 (44%) 0/5 (0%) 0.123
Enhancing tumours 17/18 (94%) 4/13 (31%) 0.000 12/18 (67%) 9/13(69%) 1.0 10/14 (71%) 11/17 (65%) 1.0
Nonenhancing or enhancement not assessable 3/4 (75%) 3/9 (33%) 0.266 5/12 (42%) 1/1 (100%) 0.462 5/10 (50%) 1/1 (100%) 1.0
Response data is given for the series as well as in subgroups according to therapy given to primary or recurrent tumour, histopathology grade, genotype and response assessment
based on enhancing tumour or T2-weighted MR. Data shows the proportion of responding cases in each group; data given as number of cases showing responset h a ti s
(CR+PR+MR)/number of cases and (%). P – probability calculated using Fisher’s exact test. Weakly significant P values are given in italics; those of greater significance are given in bold.
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(32%) with intact 1p36 and 19q13 also responded (Table 2).
Response was seen in cases that were hypermetabolic and
hypometabolic with respect to
18F-FDG uptake and in cases that
showed normal or increased
201Tl uptake. No associations between
SPECT data and response were evident in the series (Table 2), or in
subgroups of the series according to pathology subtype or grade,
therapy given to primary or recurrent cases or 1p/19q status.
Similarly, when only the 31 enhancing tumours assessed using
Macdonald criteria were considered, response was not associated
with metabolism. In the 13 cases assessed using T2-weighted
MR, response was not significantly associated with genotype
or metabolism. Analysis of semiquantitative data revealed no
associations of metabolism with response in the series overall
(Mann–Whitney test:
18F-FDG P¼0.38;
201Tl uptake P¼0.98), or
in primary (Mann–Whitney test:
18F-FDG P¼1.0;
201Tl uptake
P¼0.62) or recurrent cases (Mann–Whitney test:
18F-FDG P¼1.0;
201Tl uptake P¼0.60). When grouped according to 1p/19q status
there was no association between
18F-FDG uptake and response
(Figure 1). In cases with intact 1p/19q all responders and 9/14
nonresponders had
201Tl uptake p1 and five nonresponders (four
recurrent tumours which showed PD and one primary tumour
with SD) had increased
201Tl uptake (Figure 1). This resulted in a
statistically significant difference in
201Tl uptake between respon-
ders and nonresponders in tumours with intact 1p/19q, which was
not seen in categorical analysis (Table 2).
Survival
To compare the prognostic significance of metabolism with that
of genotype, Kaplan–Meier plots for PFS and OS following PCV
chemotherapy are given in Figure 2. Patients whose tumours
showed
18F-FDG hypermetabolism, increased
201Tl uptake or intact
1p36 and 19q13 had shorter PFS. Prolonged OS was significantly
associated with loss of 1p36 and 19q13, while tumours with
increased
201Tl uptake showed a trend toward shorter OS.
201Tl
uptake and 1p/19q genotype were independent prognostic factors
for PFS and OS in multivariate analysis (Table 3). In primary cases,
18F-FDG hypermetabolism was associated with shorter PFS (log-
rank: P¼0.0119), and trends but not significant associations
were seen between
18F-FDG uptake and OS, and between
201Tl
uptake and PFS and OS. However,
18F-FDG hypermetabolism and
increased
201Tl uptake in primary cases were both significantly
associated with shorter PFS and OS when adjusted for genotype
(log-rank: PFS:
18F-FDG P¼0.0005;
201Tl P¼0.0003; OS:
18F-FDG
P¼0.0227;
201Tl P¼0.0026) (Supplementary Data). Despite the
small number of anaplastic cases, those with
18F-FDG hyper-
metabolism had decreased PFS (log-rank P¼0.023). No significant
associations between metabolism and survival were seen in
recurrent cases, but numbers were low, especially for those with
low metabolism.
18F-FDG and
201Tl uptake enabled significant prognostic dis-
crimination for PFS in cases with or without the  1p/ 19q
genotype, but for OS only in cases with intact 1p36 and 19q13
(Figure 3). Similar findings were observed if only primary cases
were analysed (Supplementary Data).
201Tl uptake was an indepen-
dent prognostic factor for PFS and OS in multivariate analysis in
cases with intact 1p/19q (Cox Regression: PFS-HR 7.0 (95% CI 1.9–
25.5), P¼0.003; OS-HR 9.1 (95% CI 2.2–37.9), P¼0.002).
Of the 27 cases that responded to therapy, 10 had
18F-FDG
hypermetabolism and 12 had increased
201Tl uptake and elevated
metabolism was significantly associated with short PFS (log-rank
PFS:
18F-FDG P¼0.005;
201Tl P¼0.0132).
DISCUSSION
Although the association between
201Tl and
18F-FDG uptake and
adverse prognosis has been reported previously in gliomas (Higa
et al, 2001; Benard et al, 2003; Padma et al, 2003; Comte et al,
2006), this study represents the largest series of oligodendroglial
neoplasms with response and outcome data following treatment
by a uniform chemotherapeutic protocol, and is the only study to
investigate metabolism and outcome in oligodendroglial neo-
plasms classified by molecular genetics. The cohort was drawn
from a larger study of oligodendroglial neoplasms from a single
treatment centre over a 3-year period (Walker et al, 2005, 2006)
and reflects the range of patients with histopathological diagnosis
of oligodendroglial tumour given PCV chemotherapy in the
routine clinic. Associations of genotype with response and
outcome in this subgroup compared well with the larger series
that included 490% of oligodendroglial neoplasms given PCV in
the study period (Walker et al, 2006). Previously we have
shown that elevated metabolism is associated with 1p/19q loss,
as well as with increased histopathological grade (Walker et al,
2004). Elevated metabolism was significantly more common in
low-grade tumours with 1p/19q loss than in those with intact
1p/19q (Walker et al, 2004). These findings remained valid for
201Tl SPECT in the subset treated by PCV chemotherapy, but
significant associations between genotype and
18F-FDG, which
were weaker than
201Tl in the previous report, were not observed in
this subset, due to the lower numbers and reduced statistical
power. As in the previous study, increased uptake of both
18F-FDG
and
201Tl in low-grade cases was found only in those with 1p/19q
loss. The study included primary tumours given PCV as first
oncology therapy as well as those receiving PCV following
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Figure 1
18F-FDG and
201Tl uptake expressed as a ratio relative to uptake in the contralateral brain in responders (CRþPRþMR) and Nonresponders
(SDþPD) to PCV chemotherapy with and without loss of 1p36 and 19q13. (A) uptake of
201Tl, (B) uptake of
18F-FDG. P-probability by Mann–Whitney
test. Bars represent medians.
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recurrent group had a higher proportion of cases with grade III
pathology and was more likely to show increased
201Tl uptake
than primary cases. However, only 10 recurrent cases were
investigated and as gliomas progress with time, they are likely
to recur as a more aggressive tumour, which would be reflected
in their metabolism. Further study in larger series would be
necessary to explore metabolic differences between primary and
recurrent tumours.
It has been suggested that increased metabolism may be related
to therapeutic responsiveness to alkylating agents as these should
exert a more beneficial effect in tumours with higher cell turnover
and DNA-synthesis rates, which are known to correlate with higher
glucose utilisation and metabolism (Herholz et al, 1993; Brock
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Figure 2 Outcome following PCV chemotherapy. Kaplan–Meier plots of (A, C and E) PFS and (B, D and F) OS according to: – (A and B) 1p/19q
status, (C and D)
18F-FDG uptake, (E and F)
201Tl uptake. Numbers in each group indicated in parentheses. P-Probabilities calculated by the log-rank test.
Table 3 Cox regression
PFS OS
Univariate Multivariate Univariate Multivariate
P HR (95% CI) PP HR (95% CI) P
Loss of 1p36 and 19q13 (yes* vs no) 0.008 16.4 (4.5–59.4) 0.000 0.014 12.9 (3.1–54.5) 0.000
18F-FDG uptake (hypo* vs hypermetabolic) 0.008 R 0.286 NS
201Tl uptake (normal* vs increased) 0.008 14.9 (4.1–53.4) 0.000 0.045 9.5 (2.6–35.1) 0.000
Male* vs female 0.008 R 0.039 R
Histology grade (II* vs III) 0.021 R 0.042 R
Primary* vs recurrent 0.001 R 0.063 NS
Cox regression analysis for PFS and OS (n¼46) comparing SPECT data and genotype with significant clinicopathological factors. Histological subtype, presence or absence of contrast
enhancement, age and ECOG status were not significantly associated with outcome in this cohort. Data given as the hazard ratio (HR) relative to baseline (*) and 95% confidence
interval. NS – not significant in univariate analysis. P-Probability; R-term removed. Weakly significant P values are given in italics; those of greater significance are given in bold.
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set al, 2000; Prados, 2000). The methods for assessing response
used in this study are widely utilised for gliomas, despite their
limitations (Perry and Cairncross, 2003). As in other studies,
response was strongly associated with the  1p/ 19q genotype
(Cairncross et al, 1998; Ino et al, 2001; van den Bent, 2004).
Tumours with or without features of elevated metabolism showed
response following PCV chemotherapy. Elevated metabolism was
not necessary for response and no associations with response were
evident in the series as a whole or subdivisions according to grade,
enhancement, or therapy given to primary or recurrent tumours.
When subdivided by genotype, significant associations were only
seen on analysis of semiquantitative data in cases with intact 1p/
19q, where
201Tl uptake was greater in nonresponders. However,
64% of these had normal
201Tl uptake and significant differences
were not obtained in categorical analysis. Further study of a larger
series would be necessary to resolve this discrepancy. In the series
overall, response was strongly associated with the  1p/ 19q
genotype, but not metabolism, suggesting that genetic lineage is
dominant over metabolism in influencing chemosensitivity.
Metabolism measured by
201Tl or
18F-FDG uptake is not a useful
noninvasive diagnostic procedure to predict chemosensitivity in
the absence of knowledge of genotype.
Although tumours with the  1p/ 19q genotype are likely to
respond to chemotherapy, all oligodendroglial neoplasms inevi-
tably recur, with wide variations in PFS even in those with the
 1p/ 19q genotype (van den Bent, 2004). In addition, a
significant proportion of oligodendroglial neoplasms with intact
1p/19q may be chemosensitive, albeit associated with shorter PFS
than those with 1p/19q loss (Ino et al, 2001; van den Bent et al,
2003; Walker et al, 2006). Identification of factors that enable
prognostic stratification, would permit more effective clinical
management and provision of chemotherapy to patients for which
it may be of lasting benefit. In the present study, elevated
201Tl and
18F-FDG uptake were both significantly associated with shorter
PFS, in the series, in separate analysis of cases with or without the
 1p/ 19q genotype and in cases that responded to therapy.
201Tl
uptake was an independent prognostic variable in multivariate
survival analysis in the series and in cases with intact 1p/19q.
These findings suggest that SPECT data may potentially be useful
to predict cases for which chemotherapy may not be of long-term
benefit and where additional therapy should be implemented early
at the first signs of recurrence. However, the heterogeneity of the
cohort is a limitation of the study. Primary and recurrent cases
were included, although similar findings were obtained if primary
cases only were considered. Oligodendrogliomas and oligoastro-
cytomas are both commonly treated by chemotherapy and their
histopathological diagnosis is highly subjective and notoriously
difficult. Classification by molecular genetics is now widely
accepted (Reifenberger and Louis, 2003). As in our larger series,
the proportion of oligodendrogliomas with loss of 1p/19q (68%),
was lower than reported in some studies, which may reflect
diagnosis from small biopsies less prone to fixation artefact
(Walker et al, 2005). Histopathological subtype was not associated
with response or survival and elevated metabolism remained
significantly associated with outcome after adjustment for
histopathology subtype.
The most appropriate time to deliver therapy is a key question
in the clinical management of patients that present with
201Tl uptake
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Figure 3
18F-FDG and
201Tl uptake and survival in cases with or without the  1p/ 19q genotype. Kaplan–Meier plots of (A)
18F-FDG uptake and (B)
201Tl uptake comparing PFS and OS from start of PCV in cases grouped according to genotype and metabolism. Black lines – cases with 1p/19q loss, grey
lines – cases with intact 1p/19q. Solid lines normal
201Tl uptake or hypometabolic
18F-FDG uptake, dashed lines increased
201Tl or hypermetabolic
18F-FDG
uptake. Numbers in each group indicated in parentheses. Probabilities calculated by the log-rank test.
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soligodendroglial neoplasms with low-grade pathology (van den
Bent, 2004). Conventional indicators of progression to a high-
grade glioma include contrast enhancement and histopathology.
However, histopathological grading relies on subjective judgment
of morphological features and is frequently associated with inter-
observer variability (Giannini et al, 2001), while contrast
enhancement is also present in many low-grade oligodendroglial
neoplasms (Walker et al, 2005; White et al, 2005). Elevated
metabolism may also be considered an early indication of tumour
progression (Higa et al, 2001; Benard et al, 2003; Padma et al, 2003;
Vos et al, 2003; Datta et al, 2004), and in this study was seen in
both low- and high-grade tumours. However, too few grade II cases
with elevated metabolism or grade III cases with normal
metabolism were available to permit assessment of the prognostic
significance of SPECT data separately in low or high-grade cases.
In keeping with the known associations of the  1p/ 19q
genotype with prolonged survival, cases with 1p/19q loss and
elevated metabolism had longer PFS and OS than cases with intact
1p/19q and high metabolism. Intriguingly, these data suggest that
there may be differences in the thresholds at which metabolism
becomes associated with aggressive behaviour and/or differences
in the baseline biology of oligodendrogliomas with or without the
 1p/ 19q genotype. However, further studies with more biologi-
cal markers would be required to address this issue. Despite the
limitations of the study and its small heterogeneous cohort, our
findings show promise that metabolism may have prognostic
significance irrespective of genotype. Confirmation in a larger
more homogeneous series, particularly primary tumours, is
therefore essential.
From a molecular genetic viewpoint, progression in gliomas is
associated with sequential accumulation of genetic alterations with
consequent deregulation of the cell cycle and increased angio-
genesis (Hartmann et al, 2004; Jeuken et al, 2004). Upregulation of
angiogenesis factors and a variety of genetic alterations including
deletion of CDKN2A, loss of chromosome 10, downregulation of
ATase and cyclooxygenase-2 expression have been associated with
progression and poor prognosis in oligodendroglial neoplasms
(Jaeckle et al, 1998; Castilla et al, 2003; Hartmann et al, 2004;
Jeuken et al, 2004). While genetic analysis to determine the 1p/19q
status may be introduced into routine diagnostic practice, no
single test is presently available to indicate tumour progression
and poor outcome. Features of elevated metabolism in this and
other studies of oligodendrogliomas (Giammarile et al, 2004) or
gliomas (Vos et al, 2003; Pardo et al, 2004) have been associated
with poor prognosis and may result as a consequence of
deregulation of signal transduction through a variety of genetic
changes, rather than being associated with a single genetic event.
These data suggest that, in addition to the 1p/19q status, metabolic
scans may be potentially useful to predict prognosis and identify
cases with short-term benefit from PCV. This may be of greatest
utility in determining those cases with intact 1p/19q that will
benefit from chemotherapy.
In this initial study, we have shown that elevated metabolism is
not predictive of response to therapy, but may be associated with
poor survival following therapy irrespective of genotype. Further
confirmation in a larger series is therefore warranted.
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